As of Apr 25, 2025, the Sarepta Therapeutics stock's PE ratio is 24.47. This results from the current EPS of $2.47 and stock price of $60.44. The P/E ratio has a decrease of 85% from the past four quarters average of 163.9.
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 49.23 | N/A | $121.59 | $2.47 |
2023 | N/A | N/A | $96.43 | -$5.8 |
2022 | N/A | N/A | $129.58 | -$8.03 |
2021 | N/A | N/A | $90.05 | -$5.15 |
2020 | N/A | N/A | $170.49 | -$7.11 |
2019 | N/A | N/A | $129.04 | -$9.71 |
2018 | N/A | N/A | $109.13 | -$5.46 |
2017 | N/A | N/A | $55.64 | -$0.86 |
2016 | N/A | N/A | $27.43 | -$5.49 |
2015 | N/A | N/A | $38.58 | -$5.2 |
2014 | N/A | N/A | $14.47 | -$3.39 |
2013 | N/A | N/A | $20.37 | -$3.31 |
2012 | N/A | N/A | $25.8 | -$5.14 |
2011 | N/A | N/A | $4.47 | -$0.11 |
2010 | N/A | N/A | $12.72 | -$1.74 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 49.23 | -38.51% | $121.59 | $2.47 |
Sep 2024 | 80.06 | -62% | $124.89 | $1.56 |
Jun 2024 | 210.67 | -33.28% | $158 | $0.75 |
Mar 2024 | 315.76 | N/A | $129.46 | $0.41 |
Dec 2023 | N/A | N/A | $96.43 | -$5.8 |
Sep 2023 | N/A | N/A | $121.22 | -$7.83 |
Jun 2023 | N/A | N/A | $114.52 | -$10.31 |
Mar 2023 | N/A | N/A | $137.83 | -$12.69 |
Dec 2022 | N/A | N/A | $129.58 | -$8.03 |
Sep 2022 | N/A | N/A | $110.54 | -$8.22 |
Jun 2022 | N/A | N/A | $74.96 | -$5.88 |
Mar 2022 | N/A | N/A | $78.12 | -$4.25 |
Dec 2021 | N/A | N/A | $90.05 | -$5.15 |
Sep 2021 | N/A | N/A | $92.48 | -$6.13 |
Jun 2021 | N/A | N/A | $77.74 | -$8.03 |
Compared to its peer stock GILD, SRPT's PE ratio stands lower.
Stock name | PE ratio | Market cap |
---|---|---|
SRPT Sarepta Therapeutics Inc | 24.47 | $5.86B |
GILD Gilead Sciences Inc | 271.5 | $128.48B |
NVAX Novavax Inc | N/A | $1.07B |
PTCT Ptc Therapeutics Inc | N/A | $3.91B |
BCRX Biocryst Pharmaceuticals Inc | N/A | $1.75B |
ALNY Alnylam Pharmaceuticals Inc | N/A | $32.57B |
RNA Avidity Biosciences Inc | N/A | $3.71B |
INSM INSMED Inc | N/A | $12.61B |
The price to earnings ratio for SRPT stock is 24.47 as of Apr 25, 2025.
You can calculate the PE ratio by dividing the most recent stock price by the trailing twelve months EPS. As of today (Apr 25, 2025), Sarepta Therapeutics's stock price is $60.44. The earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $2.47. Therefore, Sarepta Therapeutics's P/E ratio for today is 24.47. PE RATIO(24.47) = STOCK PRICE($60.44) / TTM EPS($2.47)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.